Organization (Industry)
Vion Pharmaceuticals (United States)
ClinicalTrials.gov lists Vion Pharmaceuticals (United States) as lead sponsor of 20 trials. It has 9 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Vion Pharmaceuticals (United States): 20 lead-sponsored trials and 1 legal-entity registration.
Disease areas (47)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Leukemia, Myeloid, Acute | 8 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 6 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 5 |
| Myelodysplastic Syndromes | 5 |
| Hodgkin Disease | 4 |
Showing 5 of 47 disease areas.
Trials by start year as sponsor or collaborator (11)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2008 | 1 |
| 2007 | 2 |
| 2006 | 1 |
| 2005 | 4 |
| 2004 | 1 |
| 2003 | 4 |
| 2002 | 3 |
| 2001 | 2 |
| 2000 | 3 |
| 1999 | 1 |
Showing 10 of 11 years.
Recruitment duration, a model prediction: none of the 20 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (9)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| CYTARABINE | 4 |
| GEMCITABINE | 2 |
| HYDROXYUREA | 1 |
| CISPLATIN | 2 |
| Cefixime | 1 |
Showing 5 of 9 approved assets.
Journals published in (5)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Blood | 1 |
| Cancer chemotherapy and pharmacology | 1 |
| Clinical cancer research : an official journal of the American Association for Cancer Research | 1 |
| Clinical lymphoma, myeloma & leukemia | 1 |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 18 | 0 | 2009-10-20 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 1 |
Organization relationships (2)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 1 |
| M.D. Anderson Cancer Center | Co sponsors trial with | 1 |
Latest dated events (42)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2009-10-20 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2009-07-07 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2009-04-07 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2008-11-18 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2008-07-29 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 42 events.
Biomarker capability evidence (14)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| EGFR | Trial collaborator | Named in trial inclusion criteria |
| FGF3 | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial sponsor | Mentioned in trial text |
| ALB | Trial sponsor | Mentioned in trial text |
| ALB | Trial sponsor | Mentioned in trial text |
Showing 5 of 14 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, sponsor delivery record, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.